Density of Common Complex Ocular Traits in the Aging Eye: Analysis of Secondary Traits in Genome-Wide Association Studies by Edwards, Albert O. et al.
Density of Common Complex Ocular Traits in the Aging
Eye: Analysis of Secondary Traits in Genome-Wide
Association Studies
Albert O. Edwards
1*, Sung J. Lee
1, Brooke L. Fridley
2, Nirubol Tosakulwong
1
1Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, United States of America, 2Division of Biostatistics, Mayo Clinic, Rochester, Minnesota, United States
of America
Abstract
Genetic association studies are identifying genetic risks for common complex ocular traits such as age-related macular
degeneration (AMD). The subjects used for discovery of these loci have been largely from clinic-based, case-control studies.
Typically, only the primary phenotype (e.g., AMD) being studied is systematically documented and other complex traits (e.g.,
affecting the eye) are largely ignored. The purpose of this study was to characterize these other or secondary complex
ocular traits present in the cases and controls of clinic-based studies being used for genetic study of AMD. The records of
100 consecutive new patients (of any diagnosis) age 60 or older for which all traits affecting the eye had been recorded
systematically were reviewed. The average patient had 3.5 distinct diagnoses. A subset of 10 complex traits was selected for
further study because they were common and could be reliably diagnosed. The density of these 10 complex ocular traits
increased by 0.017 log-traits/year (P=0.03), ranging from a predicted 2.74 at age 60 to 4.45 at age 90. Trait-trait association
was observed only between AMD and primary vitreomacular traction (P=0.0009). Only 1% of subjects age 60 or older had
no common complex traits affecting the eye. Extrapolations suggested that a study of 2000 similar subjects would have
sufficient power to detect genetic association with an odds ratio of 2.0 or less for 4 of these 10 traits. In conclusion, the high
prevalence of complex traits affecting the aging eye and the inherent biases in referral patterns leads to the potential for
confounding by undocumented secondary traits within case-control studies. In addition to the primary trait, other common
ocular phenotypes should be systematically documented in genetic association studies so that adjustments for potential
trait-trait associations and other bias can be made and genetic risk variants identified in secondary analyses.
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Introduction
The eye has long been an excellent organ for studying
hereditary diseases, in part, because the visual system enables
use of our discriminating sense of vision to characterize
phenotypes. Genetic association studies on age-related macular
degeneration (AMD, Online Mendelian Inheritance of Man,
OMIM, 603075), cataract (OMIM 601371), glaucoma (OMIM
137760), and other diseases are unraveling the genetic risks for
common complex ocular traits [1–3]. Other common diseases
such as epiretinal membranes are not known to be hereditary, but
could influence study endpoints through biases in referral patterns
or unknown genetic effects. Genetic association studies have
proven a powerful method and important genetic risks have been
identified for systemic age-related complex traits such as cancer
and coronary artery disease [4,5]. Many of these studies use clinic-
based case-control subjects ascertained for the presence or absence
of the primary trait (e.g., AMD) and systematically document
phenotypes on few, if any, other complex ocular traits [6–10].
The unavailability of phenotypes on other (secondary) ocular
traits in a case-control study gives rise to a number of limitations.
Because such clinic based studies are collected from a number of
different subspecialty clinics, the inability to account for the
diagnoses for which the patient presented could lead to undetected
confounding of genetic results. Trait-trait associations that might
confound the interpretation of association results, such as the
reported increased risk of exudative AMD in eyes with posterior
vitreous adherence to the macula or Fuchs endothelial dystrophy
(OMIM 610158), cannot be assessed [11–14]. Genetic risks may
alter the risk of related diseases, such as the common risk on
chromosome 8q24 for cancer, and it is well established that
Mendelian diseases can affect multiple tissues with diseases
indistinguishable from the complex traits affecting the eye
[4,15,16]. Such shared risks are likely to be missed in the absence
of systematic phenotyping of common traits affecting an organ.
Equally important to these potential problems is the inability to
explore genotypes generated in genome-wide studies for associa-
tion with secondary ocular traits or even the large number of
biomorphic and biochemical variables such as axial length of the
eye, corneal thickness, and retinal autofluorescence that influence
disease progression [17–19]. Indeed, some common complex
traits, biomorphic features, and biochemical endpoints might
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lack of value due to the high cost of genetic association studies and
the low rate of uncorrectable vision loss due to mild severity or the
availability of surgical interventions.
A great deal of work goes into the ascertainment of subjects for
disease-specific case-control studies. Some of this effort is specific
to each disease. However other factors such as fundus photographs
of the macula in studies of AMD can also be used to study the
retinal vasculature (e.g., occlusions) and optic nerve (e.g.,
glaucoma). Similarly, activities such as consent, eye examination,
phlebotomy, isolation of genomic DNA, and genotyping would
apply to all traits initially. Environmental exposures such as
tobacco smoking and body mass index alter the risk of multiple eye
diseases and the effort to collect this information would be
applicable to a number of complex traits affecting the eye [20–24].
Certainly, there are complex traits that would require collection of
unique medical history information such as asking about atopic
dermatitis in a study of retinal detachment; however, most of the
answers would be negative and our impression is that the
additional work is probably modest. Nonetheless, the documen-
tation of other traits and biomorphic variables would modestly
increase the cost of ascertainment, while also greatly increasing the
value of the study.
One might argue that the use of clinic-based case-control studies
should be minimized in favor of population-based case-control
cohorts or family studies as more robust designs for avoiding
possible confounding and biases [25,26]. The major limitation of
using these methods is the expense of identifying large numbers of
subjects with and without the full spectrum of the primary trait.
While population-based case-control studies may be ideal for gene
discovery, such studies are rarely available because the full expense
of the recruitment, diagnoses, and documentation must be covered
by the research program. Family-based association is an excellent
strategy for early-onset diseases, but is difficult to apply to age-
related disease where the parents of the proband are often
deceased [27]. Thus, clinic-based, case-control studies are a
valuable tool for gene discovery because large numbers of subjects
can be rapidly and efficiently ascertained and evaluated in a
systematic manner. They are likely to continue to be a primary
method used in genetic association studies of ocular traits.
The purpose of this study was to better understand the other
complex ocular traits affecting the aging eye in the types of clinic-
based, case-control studies currently being used by us and others to
study the genetics of AMD and other traits. To this end, we
documentedthe density of complex traits present in100consecutive
patients age 60 or older attending a referral-based vitreoretinal
clinic. This information was used to explore the additional
information that might be gained by considering secondary ocular
traits in genetic-epidemiology studies. The study revealed that most
patients age 60 older have greater than 3 distinct diseases affecting
their eyes, that most of these diseases were common ocular traits,
and that they were typically present at a similar or higher frequency
as population estimates. Controls without any other common and
potentially hereditary eye diseases were rare. Rather than ignoring
the potential confounding of secondary traits, we propose an
alternative strategy in which subjects selected based on the presence
of a disease be characterized for all other common diseases within
that organ system. This approach would enable the detection of
genetic risks for secondary traits while accounting for any
stratification, confounding, or association between traits and other
variables using standard statistical methods. The proposed ‘‘mul-
tiple-trait case-control study’’ employing several binary traits is
analogous to traditional cohort studies in which the incidence of
multiple quantitative traits are ascertained. These observations are
important for the design of large-scale genome-wide association
studies studying ocular traits and possibly for the study of other
organ systems.
Results
Density of Complex Ocular Traits
In order to determine the density (number of traits per patient)
of traits affecting the aging eye, the systematically documented
diagnoses of 100 consecutive patients seen in the clinic for the first
time for any reason from one retinal specialist were extracted from
the medical record (Table 1). An average of 3.5 distinct diagnoses
was observed in the 100 consecutive patients (Table 2). The 10
common complex traits listed in Table 1 accounted for 2.5 of these
distinct diagnoses (Table 2). Only one of the 100 patients did not
have at least 1 of the 10 common complex traits listed in Table 1.
The density of complex traits in the 45 males was 2.5 compared to
2.6 in the 55 females (P=0.70, Poisson regression).
Effect of Age on Density of Complex Ocular Traits
A scatter plot of year of age versus the density of the ten
complex ocular traits listed in Table 1 for each patient shows a
trend toward an increase in density with age (Figure 1A). Poisson
regression modeling showed an effect of age (P=0.03) and
estimated a rate of increase of 0.01760.0074 log-number of
complex traits per year across the age range represented in this
study (ages 60–94). Using logistic regression, AMD (P,0.0001)
and glaucoma (P=0.01) were observed to increase with age
(Figure 1B), while the frequency of posterior vitreous detachment
(PVD) and vitreomacular traction (VMT) were not influenced by
age. An effect of age was not observed for the combined frequency
of the 8 complex traits remaining after removing AMD and
glaucoma from the analysis (P=0.66).
Gender-Trait, and Trait-Trait Associations
Exploratory analyses were performed looking for gender-trait
and trait-trait associations. Fisher’s exact test was used to test for
association with gender for all traits with at least 5 patients with the
trait and 5 patients without the trait. No gender-trait association
was observed for Fuchs, AMD, glaucoma, PVD, VMT, retinal
vascular occlusion (RVO), or retinal tears. The low frequency of
conditions thought to be associated with gender (e.g., VMT), may
explain the failure to observe an association.
Trait-trait associations were assessed for each of the ten complex
traits having at least 10 patients with and 10 patients without the
trait (AMD, Glaucoma, PVD, VMT). The only significant
association was AMD with VMT (P=0.0009) in which VMT
was protective. The distribution was as follows: AMD/VMT 4,
AMD/No VMT 50, No AMD/VMT 16, and No AMD/No
VMT 30. Since both eyes were always examined, it is unlikely that
the VMT obscured the diagnosis of AMD, which usually affects
both eyes. This observation probably reflects a referral bias in
which patients with AMD and VMT are not referred for surgery
for VMT, thus leading to a decrease in the number of subjects
with AMD and VMT.
Modeling of power to detect association with secondary
traits in a genetic association study
We sought to determine the odds-ratio of a genetic effect that
could be detected in a case-control study based on this clinic-based
study. Using the frequencies of traits observed in the 100-person
sample, we extrapolated to a similar hypothesized clinic-based
sample of 2000 subjects. The 2000 subjects effectively form a
cross-sectional study, where one defines diseased and not-diseased
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odds-ratios for each genetic variant (a case-control study). The
analysis enabled an estimation of the information on secondary
traits that would be ignored in most ocular case-control studies.
Specifically, we tested the hypothesis that comprehensive pheno-
typing of common ocular traits would enable discovery of genetic
risks for secondary traits. The genotype data would be re-analyzed
after re-coding cases and controls based on each secondary trait.
The analysis showed that even this primitive ascertainment
strategy, without any effort to increase the representation of less
common traits, would have enabled detection of genetic risks for
most of the traits (see Table 1 for observed frequencies of each
trait). For example, at a significance level of 0.05, a modest
genotypic effect of OR=2.0 would have been detected in 6 of the
10 traits when the minor allele frequency was between 0.10 and
0.20 and 9 of the 10 traits when the minor allele frequency was
0.40 (Table 3). There was sufficient power to detect odds-ratios of
1.7, 1.7, 1.6, and 1.6 for the four most common traits glaucoma,
PVD, AMD, and VMT, respectively. When the number of
markers tested increases, as in the case of genome-wide association
studies with a significance level of 0.00001, a modest genotypic
effect of OR=2.0 would have been detected in 4 out of the 10
traits when the minor allele frequency was 0.20 and 6 out of 10
traits when the minor allele frequency was 0.40 (Table 3).
Discussion
We show that the average patient age 60 or older has at least 3.5
distinct ocular diseases or traits, and that the majority of these
diseases arise from common complex traits affecting the eye.
Further, we show that some traits steadily increase with age, but
that others do not appear to increase after the age of 60 years.
Finally, we show that comprehensive documentation of secondary
common complex traits affecting the aging eye would substantially
increase the value of a genome-wide genetic association study.
We chose to use clinic-based cases and controls from a
subspecialty clinic, because this represents the most common
method used to ascertain patients for genetic case-control studies
of eye diseases. Such samples are easily collected during the course
of routine patient care. Further, large numbers of affected subjects
with broad representation of the spectrum of disease and its
complications can be collected in this manner, which is typically
not possible with population-based approaches due to financial
constraints. It is important to realize the limitations of clinic-based,
case-control studies. The frequencies of traits do not necessarily
reflect the underlying population prevalence and they tend to
over-estimate population parameters such as relative risks and
attributable fractions. Further, replication is essential for all genetic
association results, regardless of the study design [28].
Table 2. Density of complex ocular traits in 100 consecutive patients age 60 or older arranged by presenting diagnosis.
Presenting Diagnosis
Number of
Patients
Average number (standard
error) of distinct diagnosis
for the 20 observed traits
Average number (standard
error) of the 10 complex
traits in Table 1
Range of the 10 complex
traits in Table 1
Age-related macular degeneration 47 3.7 (0.19) 2.9 (0.12) 1–5
Vitreomacular traction 22 3.7 (0.27) 2.8 (0.17) 2–4
Diabetic retinopathy 8 2.6 (0.18) 1.4 (0.18) 1–2
Retinal vascular occlusion (all BRVO) 4 4.8 (0.48) 3.8 (0.48) 3–5
Other 19 2.9 (0.30) 1.8 (0.22) 0–4
All patients 100 3.5 (0.13) 2.6 (0.10) 0–5
doi:10.1371/journal.pone.0002510.t002
Table 1. Common complex traits documented in 100 consecutive patients.
Ocular region or
tissue Disease name (abbreviation)
Evidence for
hereditary
component
Prevalence
(%) in retina
clinic patients
Estimate for
Prevalence (%) in
North America*
Cornea Anterior basement membrane dystrophy (ABMD, OMIM 121820) Minimal[57] 1 5
Fuchs endothelial corneal dystrophy (Fuchs) Strong[56,58] 7 10
Lens Cataract, age-related Strong[59,60] 96 50
Pseudoexfoliation (PXE, OMIM 177650) Strong[3] 3 5
Multiple Glaucoma, open or closed angle or syndrome predisposing to glaucoma
except for PXE
Strong[51,61] 12 5
Vitreous Posterior vitreous detachment (PVD, No OMIM number) Unknown 54 50
Macula Age-related macular degeneration (AMD) Strong[1] 54 15
Vitreomacular traction (Epiretinal membrane and macular hole, VMT;
No OMIM number)
Minimal[62–64] 20 10
Retina Occlusive retinal vascular disease (RVO; No OMIM number) Minimal[65,66] 7 2
Retinal tears (with or without detachment; No OMIM number) Strong[67] 5 3
*Please refer to the Discussion for an explanation of these approximate population estimates for individuals age 60 or older.
doi:10.1371/journal.pone.0002510.t001
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potential for selection bias and the possibility of confounding due
to unmeasured differences between case and control status that are
associated with genetic exposures. One manner is which this could
arise might be from referral patterns to the specific physicians from
which the case or control subjects are being collected. Thus, an
additional benefit of documentation of secondary complex traits
affecting the eye would be to account for such effects using
standard statistical techniques. At this time it is largely unknown if
this type of confounding exists in genetic association studies of
ophthalmic or other traits. Thus, our identification of association
between vitreomacular traction and AMD is of particular interest.
The observation that patients with vitreomacular traction were less
likely to have AMD, was unexpected because previous studies
have suggested it might be a risk factor for exudative AMD
[11,13,29]. Our observation likely is due to referral biases, where
patients with vitreomacular traction who also had AMD were not
referred for surgical management.
Even though the examiner of the 100 consecutive subjects in
this study routinely documents all ocular traits including the ten in
Table 1, we recognize that traits are missed due to the distractions
that occur in a busy clinic. Thus, our estimate of the density of
common complex traits is very likely under-estimated. Prospective
examination with photographic documentation and quantitative
Figure 1. Scatter plot showing the density (number of distinct traits per patient) of the 10 complex ocular traits listed in Table 1
versus age for all 100 patients. A, The plotted points are the observed data and the line depicts the modeled relationship between age and
density. B, The modeled probability of patients having AMD and glaucoma as a function of age using the logistic regression model.
doi:10.1371/journal.pone.0002510.g001
Table 3. Odds-ratio for association between genotypes and traits that might be detected with a power of 0.8 at the specified
minor allele frequency.
Complex
ocular trait*
Number
with trait
Number
without trait
Odds-ratio** at a minor allele
frequency of 0.1 ***
Odds-ratio at a minor allele
frequency of 0.2***
Odds-ratio at a minor allele
frequency of 0.4***
0.05 0.001 0.00001 0.05 0.001 0.00001 0.05 0.001 0.00001
ABMD 20 1980 3.25 5.20 7.90 2.70 4.10 6.10 2.50 4.00 6.30
Fuchs 140 1860 1.70 2.10 2.60 1.50 1.80 2.10 1.45 1.70 1.95
Cataract 1920 80 2.25 3.60 5.80 1.80 2.45 3.25 1.60 2.15 2.50
PXE 60 1940 2.10 2.80 3.60 1.80 2.35 2.90 1.70 2.15 2.70
Glaucoma 240 1760 1.55 1.80 2.10 1.40 1.60 1.80 1.35 1.50 1.70
PVD 1080 920 1.35 1.60 1.80 1.25 1.40 1.55 1.20 1.30 1.45
AMD 1080 920 1.35 1.55 1.70 1.25 1.40 1.50 1.20 1.30 1.40
VMT 400 1600 1.45 1.65 1.90 1.35 1.50 1.65 1.25 1.40 1.55
RVO 140 1860 1.70 2.05 2.45 1.50 1.80 2.10 1.45 1.70 1.95
Retinal tears 100 1900 1.80 2.30 2.80 1.60 2.00 2.35 1.50 1.85 2.15
*Abbreviations and definitions are given in Table 1.
**Power was estimated assuming a log-additive genetic model, significance levels of 0.05, 0.001, and 0.00001, complete linkage disequilibrium between the single
nucleotide polymorphism (SNP) studied and the genetic variant underlying the association, and the population prevalence estimates shown in Table 1.
***The three significance levels, namely 0.05, 0.001, and 0.00001, refer to testing one variant, multiple variants in a single gene, and variants across the genome,
respectively.
doi:10.1371/journal.pone.0002510.t003
Density Complex Ocular Traits
PLoS ONE | www.plosone.org 4 June 2008 | Volume 3 | Issue 6 | e2510grading would be preferred when possible for genetic association
studies. Nonetheless, we sought to compare the observed
frequency of complex traits in our 100 patients to the previous
reports of prevalence of the ten common complex traits (Table 1),
because this information is important in designing future studies
using case-control studies.
Prevalence studies of corneal guttae have not been performed in
North American populations. The Reykjavik study estimated an
overall 9% prevalence in a Caucasian population, while a study on
Asians estimated 3.5% to 6.5% depending on the population
[30,31]. ABMD may be present in about 5% of the population,
based on a prior prevalence study in North Americans [32]. The
prevalence of cataract was estimated to be about 50% [33,34].
The much higher prevalence in our patients is due to the
difference in definition of the age-related lens changes to diagnose
a cataract, since almost all patients have some age-related lens
change by the age of 60. Use of one of the quantitative scales
would be preferred for a genetic association study [35]. The
prevalence of pseudoexfoliation varies greatly across populations,
and no previous studies appeared to be a good fit the population of
Minnesota and an estimate of 5% was assumed based on other
populations [36–38].
The much higher prevalence of AMD in our patients, compared
to the population estimate of 15%, is due to referral bias, since this
was the leading cause of presenting diagnosis [39]. The population
prevalence of glaucoma is about 5% based on the Beaver Dam
study [40].The observed prevalence of posterior vitreous separation
inourstudywassimilar topublished reports [41]. Theprevalence of
epiretinal membranes and retinal vascular occlusion in the Blue
Mountains Eye Study was about 10%, and 2% respectively [42,43].
The prevalence of retinal tears in autopsy eyes was 3.3% [44].
These latter three traits are also common reasons for referral. Thus,
with the exception of the traits representing common reasons for
referral to the examiner and the lower threshold for diagnosis of
cataract, the observed prevalence of these 10 complex traits is a
reasonable approximation to published reports (Table 1). It was
notable how little prevalence information, population-based or
otherwise, was actually available for most common ocular traits in
North America.
Genetic association studies on age-related ocular traits often use
age 60 or older for controls, under the assumption that subjects in
this age range are unlikely to develop the trait under study at a
later age. Our observation of a steady increase in the density of
complex traits with age might be explained by only older subjects
symptomatic or having vision threatening eye diseases coming to
the clinic. We have no method for controlling for this possibility,
but our observations are consistent with the already established
increase in disease prevalence for AMD, glaucoma, and RVO
[40,43,45]. Further, for PVD which is known to stabilize with age,
we did not observe an age-dependent increase [46]. Thus, the
selection of an age-cut off for controls should be selected based
upon the age-dependent prevalence of the disease or preferably
either frequency or exact matched for age. The commonly held
opinion that age 60 is the lowest acceptable minimal age for
controls used in studies on AMD, glaucoma, and other eye traits is
not supported by our data.
In addition to these complex traits affecting the eye, there are a
number of quantitative biomorphic and biochemical variables of
interest in eye development and disease risk. For example, central
corneal thickness has been associated with risk of development of
glaucoma and many investigators believe that macular pigment
and macular autofluorescence alter the risk of macular degener-
ation [17,19,47]. Although there are few studies exploring the
heritability of such quantitative variables in humans, available
evidence suggests that biomorphic ocular variables are highly
hereditary [48–52]. In addition to demographic and epidemio-
logical variables such as dietary and drug exposures, these
variables should be considered for inclusion in a comprehensive
study of complex ocular traits.
The density of complex traits in these patients and our modeling
studies suggest that future studies of complex ocular traits would
benefit from the systematic documentation of secondary traits. An
ascertainment strategy that focused on the diseases of highest priority
(e.g., AMD, glaucoma, Fuchs, cataract) could be employed to
optimize the case-control study for detection of other traits of
secondary interest. There is substantial evidence that many of the
common traits have genetic influences, as illustrated in Table 1. Of
course, the lack of strong evidence does not imply the absence of a
genetic effect as was recently demonstrated for pseudoexfoliation [3].
Inclusion of biomorphic and biochemical endpoints would further
expand the value of the study. This type of approach would offer
advantages over the standard approach looking at a single trait
includingtheabilitytolookforsharedgeneticrisksdirectly,theability
to detect trait-trait association, and overall lower cost. Although our
model for this study was the aging eye, there is evidence that similar
concepts apply to other organs such as the skin [53].
A number of study designs are available to study common
complex traits. The Wellcome Trust Case Control Consortium
used a pool of unexamined subjects as the controls for each of the
seven traits studied [54]. While this is a reasonable approach, it
does not appear to have any major advantages over sequentially
studying secondary traits in a case-control study. For example,
both could be influenced by referral biases and geographic
differences in genetics or exposures. Further, the unexamined
control strategy results in loss of power for very common traits,
because a certain proportion of the controls have disease. The
approach we are suggesting can control for the various biases in
subject ascertainment and exposures, maximizes power because all
subjects are phenotyped, and minimizes genotyping costs because
most (or all) subjects have one or more diseases of clinical interest.
Methods
Patient chart review
This retrospective chart review was approved by the institu-
tional review board of the Mayo Clinic and patient consent was
not required. The data was extracted twice and any discrepancies
resolved by the first author. The initial visit was reviewed first and
subsequent visits reviewed to look for diseases present at the first
examination, but that were not documented. Although this study is
retrospective, the retina specialist performed a systematic and
comprehensive eye examination documenting all ocular diagnoses,
including the complex traits listed in Table 1 on all patients
examined during their initial visit. Note that these common traits
extracted from the medical record were selected in advance, prior
to the start of the study, because they are documented on most
visits due to their relevance to the performance or complications of
surgery and/or potential impact on vision. Thus, the number of
diagnoses overlooked is expected to be modest. Age and gender
were recorded in order to stratify the density of complex traits by
these two variables. The final diagnosis underlying the reason for
the patient’s initial consultation was recorded as the presenting
diagnosis. Ethnicity was not considered in the analysis because
over 90% of the patients were Caucasian, reflecting the frequency
of this population in southeastern Minnesota.
The diagnostic criteria followed standard clinical criteria. The
diagnosis of AMD was made based on a published classification
system [55]. Fuchs was diagnosed based on having two or more
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was diagnosed based on any discoloration or opacification of the
nucleus or cortex or prior cataract surgery, PVD based on the
presence of a Weiss ring or a visible posterior hyaloid by
examination or ultrasound. Glaucoma was based on optic nerve
damage attributed to glaucoma. The other diseases were
documented using standard clinical criteria.
Primary complex traits and all distinct diagnoses were recorded.
Complications of primary diseases, such as retinal edema from
branch retinal vein occlusions, were not extracted. Refractive
errors were not recorded because of the absence of refractive status
prior to cataract surgery and the absence of important refractive
components such as axial length. Posterior staphylomata from
high myopia were not recorded because of the lack of an
ophthalmic ultrasound to record the diagnosis accurately, but
myopic degeneration of the RPE and retina was recorded as an
accurate marker of myopic degeneration. Secondary diagnoses
such as epiretinal membranes from trauma or glaucoma from
surgical complications were not included. Drusen insufficient to
meet the diagnosis of AMD were not considered a diagnosis.
Extraocular conditions such as blepharitis and ptosis were not
extracted.
Statistical analysis
This study was primarily descriptive with the goal of
determining the density (number per patient) of complex ocular
traits affecting a clinic-based study of patients age 60 or older.
Poisson regression models were fit to assess the effect of age and
gender on the density of the 10 complex ocular traits in Table 1
and likelihood ratio rests were used to assess the significance of age
and gender. Fisher’s exact tests were used to test for association
between the presence or absence of a trait and gender (trait-
gender) and another trait (trait-trait). Logistic regression was used
to model the association between traits (presence or absence) and
age and tests for association were completed using likelihood ratio
tests. Significance results (p-values) are presented without correc-
tion for multiple testing.
Modeling of power to detect association with secondary
traits in a genetic association study
The traits observed in the 100 consecutive patients were
extrapolated to create a hypothetical clinic-based study of 2000
patients. The odds-ratio that could be detected with power of 0.8
given the frequency of each trait and a minor allele frequency of
0.1, 0.2, and 0.4 were calculated. Power for the main analysis of
AMD and the secondary eye traits was computed assuming a log-
additive genetic model, complete linkage disequilibrium between
the SNP and the causative variant, and a population-based
estimate of the prevalence of each trait. Varying significance levels
were used to adjust for multiple testing of many variants, namely,
0.05 for one variant, 0.001 for multiple variants in a single gene,
and 0.00001 for multiple variants across the genome.
Acknowledgments
We thank Drs. James Cerhan, Gloria Peterson, and other members of the
Mayo Clinic Division of Biostatistics for helpful discussions.
Author Contributions
Conceived and designed the experiments: AE BF. Performed the
experiments: AE SL NT. Analyzed the data: AE BF. Contributed
reagents/materials/analysis tools: AE BF NT. Wrote the paper: AE BF.
References
1. Edwards AO, Malek G (2007) Molecular genetics of AMD and current animal
models. Angiogenesis in press.
2. Matsuda A, Ebihara N, Kumagai N, Fukuda K, Ebe K, et al. (2007) Genetic
polymorphisms in the promoter of the interferon gamma receptor 1 gene are
associated with atopic cataracts. Invest Ophthalmol Vis Sci 48: 583–589.
3. Thorleifsson G, Magnusson KP, Sulem P, Walters GB, Gudbjartsson DF, et al.
(2007) Common sequence variants in the LOXL1 gene confer susceptibility to
exfoliation glaucoma. Science 317: 1397–1400.
4. Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, et al.
(2006) Admixture mapping identifies 8q24 as a prostate cancer risk locus in
African-American men. Proc Natl Acad Sci U S A 103: 14068–14073.
5. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, et al. (2007) A
common allele on chromosome 9 associated with coronary heart disease. Science
316: 1488–1491.
6. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, et al. (2005)
Complement factor H polymorphism and age-related macular degeneration.
Science 308: 421–424.
7. Li M, Atmaca-Sonmez P, Othman M, Branham KE, Khanna R, et al. (2006)
CFH haplotypes without the Y402H coding variant show strong association with
susceptibility to age-related macular degeneration. Nat Genet 38: 1049–1054.
8. Conley YP, Jakobsdottir J, Mah T, Weeks DE, Klein R, et al. (2006) CFH,
ELOVL4, PLEKHA1 and LOC387715 genes and susceptibility to age-related
maculopathy: AREDS and CHS cohorts and meta-analyses. Hum Mol Genet
15: 3206–3218.
9. Maller J, George S, Purcell S, Fagerness J, Altshuler D, et al. (2006) Common
variation in three genes, including a noncoding variant in CFH, strongly
influences risk of age-related macular degeneration. Nat Genet 38: 1055–
1059.
10. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, et al. (2005)
Complement factor H variant increases the risk of age-related macular
degeneration. Science 308: 419–421.
11. Krebs I, Brannath W, Glittenberg C, Zeiler F, Sebag J, et al. (2007) Posterior
vitreomacular adhesion: a potential risk factor for exudative age-related macular
degeneration? Am J Ophthalmol 144: 741–746.
12. Schmidt JC, Mennel S, Horle S, Meyer CH (2006) High incidence of
vitreomacular traction in recurrent choroidal neovascularisation after repeated
photodynamic therapy. Br J Ophthalmol 90: 1361–1362.
13. Ondes F, Yilmaz G, Acar MA, Unlu N, Kocaoglan H, et al. (2000) Role of the
vitreous in age-related macular degeneration. Jpn J Ophthalmol 44: 91–93.
14. Rao GP, Kaye SB, Agius-Fernandez A (1998) Central corneal endothelial guttae
and age-related macular degeneration: is there an association? Indian J
Ophthalmol 46: 145–147.
15. Lee MM, Ritter R 3rd, Hirose T, Vu CD, Edwards AO (2003) Snowflake
vitreoretinal degeneration: follow-up of the original family. Ophthalmology 110:
2418–2426.
16. Hejtmancik JF, Jiao X, Li A, Sergeev YV, Ding X, et al. (2008) Mutations in
KCNJ13 cause autosomal dominant snowflake vitreoretinal degeneration. Am J
Hum Genet in press.
17. Brandt JD, Beiser JA, Kass MA, Gordon MO (2001) Central corneal thickness in
the Ocular Hypertension Treatment Study (OHTS). Ophthalmology 108:
1779–1788.
18. Szijarto Z, Schvoller M, Poto L, Kuhn F, Kovacs B (2007) Pseudophakic retinal
detachment after phacoemulsification. Ann Ophthalmol (Skokie) 39: 134–139.
19. Schmitz-Valckenberg S, Bindewald-Wittich A, Dolar-Szczasny J, Dreyhaupt J,
Wolf S, et al. (2006) Correlation between the area of increased autofluorescence
surrounding geographic atrophy and disease progression in patients with AMD.
Invest Ophthalmol Vis Sci 47: 2648–2654.
20. Hyman LG, Lilienfeld AM, Ferris FLd, Fine SL (1983) Senile macular
degeneration: a case-control study. Am J Epidemiol 118: 213–227.
21. Zoega GM, Fujisawa A, Sasaki H, Kubota A, Sasaki K, et al. (2006) Prevalence
and risk factors for cornea guttata in the Reykjavik Eye Study. Ophthalmology
113: 565–569.
22. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL 3rd (2005) Risk factors
for the incidence of Advanced Age-Related Macular Degeneration in the Age-
Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology
112: 533–539.
23. Nakano T, Tatemichi M, Miura Y, Sugita M, Kitahara K (2005) Long-term
physiologic changes of intraocular pressure: a 10-year longitudinal analysis in
young and middle-aged Japanese men. Ophthalmology 112: 609–616.
24. Budenz DL, Anderson DR, Feuer WJ, Beiser JA, Schiffman J, et al. (2006)
Detection and prognostic significance of optic disc hemorrhages during the
Ocular Hypertension Treatment Study. Ophthalmology 113: 2137–2143.
25. Hopper JL, Bishop DT, Easton DF (2005) Population-based family studies in
genetic epidemiology. Lancet 366: 1397–1406.
26. Clayton D, McKeigue PM (2001) Epidemiological methods for studying genes
and environmental factors in complex diseases. Lancet 358: 1356–1360.
27. Laird NM, Lange C (2006) Family-based designs in the age of large-scale gene-
association studies. Nat Rev Genet 7: 385–394.
Density Complex Ocular Traits
PLoS ONE | www.plosone.org 6 June 2008 | Volume 3 | Issue 6 | e251028. Dahlman I, Eaves IA, Kosoy R, Morrison VA, Heward J, et al. (2002)
Parameters for reliable results in genetic association studies in common disease.
Nat Genet 30: 149–150.
29. Weber-Krause B, Eckardt U (1996) [Incidence of posterior vitreous detachment
in eyes with and without age-related macular degeneration. An ultrasonic study].
Ophthalmologe 93: 660–665.
30. Khan AO (2006) Reykjavik Eye Study and cornea guttata. Ophthalmology 113:
2374–2375; author reply 2375.
31. Kitagawa K, Kojima M, Sasaki H, Shui YB, Chew SJ, et al. (2002) Prevalence of
primary cornea guttata and morphology of corneal endothelium in aging
Japanese and Singaporean subjects. Ophthalmic Res 34: 135–138.
32. Werblin TP, Hirst LW, Stark WJ, Maumenee IH (1981) Prevalence of map-dot-
fingerprint changes in the cornea. Br J Ophthalmol 65: 401–409.
33. Mitchell P, Cumming RG, Attebo K, Panchapakesan J (1997) Prevalence of
cataract in Australia: the Blue Mountains eye study. Ophthalmology 104:
581–588.
34. Klein BE, Klein R, Linton KL (1992) Prevalence of age-related lens opacities in
a population. The Beaver Dam Eye Study. Ophthalmology 99: 546–552.
35. Chylack LT, Jr., Wolfe JK, Singer DM, Leske MC, Bullimore MA, et al. (1993)
The Lens Opacities Classification System III. The Longitudinal Study of
Cataract Study Group. Arch Ophthalmol 111: 831–836.
36. Young AL, Tang WW, Lam DS (2004) The prevalence of pseudoexfoliation
syndrome in Chinese people. Br J Ophthalmol 88: 193–195.
37. Arnarsson A, Damji KF, Sverrisson T, Sasaki H, Jonasson F (2007)
Pseudoexfoliation in the Reykjavik Eye Study: prevalence and related
ophthalmological variables. Acta Ophthalmol Scand 85: 822–827.
38. Mitchell P, Wang JJ, Hourihan F (1999) The relationship between glaucoma and
pseudoexfoliation: the Blue Mountains Eye Study. Arch Ophthalmol 117:
1319–1324.
39. Friedman DS, O’Colmain BJ, Munoz B, Tomany SC, McCarty C, et al. (2004)
Prevalence of age-related macular degeneration in the United States. Arch
Ophthalmol 122: 564–572.
40. Klein BE, Klein R, Sponsel WE, Franke T, Cantor LB, et al. (1992) Prevalence
of glaucoma. The Beaver Dam Eye Study. Ophthalmology 99: 1499–1504.
41. Snead MP, Snead DR, Richards AJ, Harrison JB, Poulson AV, et al. (2002)
Clinical, histological and ultrastructural studies of the posterior hyaloid
membrane. Eye 16: 447–453.
42. Mitchell P, Smith W, Chey T, Wang JJ, Chang A (1997) Prevalence and
associations of epiretinal membranes. The Blue Mountains Eye Study, Australia.
Ophthalmology 104: 1033–1040.
43. Mitchell P, Smith W, Chang A (1996) Prevalence and associations of retinal vein
occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 114:
1243–1247.
44. Straatsma BR (1980) Peripheral retinal tears: classification, prevalence and
principles of management. Aust J Ophthalmol 8: 275–279.
45. Klein R, Klein BE, Linton KL (1992) Prevalence of age-related maculopathy.
The Beaver Dam Eye Study. Ophthalmology 99: 933–943.
46. Snead MP, Snead DR, Mahmood AS, Scott JD (1994) Vitreous detachment and
the posterior hyaloid membrane: a clinicopathological study. Eye 8 (Pt 2):
204–209.
47. Whitehead AJ, Mares JA, Danis RP (2006) Macular pigment: a review of current
knowledge. Arch Ophthalmol 124: 1038–1045.
48. He M, Wang D, Zheng Y, Zhang J, Yin Q, et al. (2008) Heritability of anterior
chamber depth as an intermediate phenotype of angle-closure in Chinese: the
Guangzhou Twin Eye Study. Invest Ophthalmol Vis Sci 49: 81–86.
49. Zhu G, Hewitt AW, Ruddle JB, Kearns LS, Brown SA, et al. (2007) Genetic
Dissection of Myopia Evidence for Linkage of Ocular Axial Length to
Chromosome 5q. Ophthalmology.
50. Peet JA, Cotch MF, Wojciechowski R, Bailey-Wilson JE, Stambolian D (2007)
Heritability and familial aggregation of refractive error in the Old Order Amish.
Invest Ophthalmol Vis Sci 48: 4002–4006.
51. van Koolwijk LM, Despriet DD, van Duijn CM, Pardo Cortes LM,
Vingerling JR, et al. (2007) Genetic contributions to glaucoma: heritability of
intraocular pressure, retinal nerve fiber layer thickness, and optic disc
morphology. Invest Ophthalmol Vis Sci 48: 3669–3676.
52. Chen CY, Scurrah KJ, Stankovich J, Garoufalis P, Dirani M, et al. (2007)
Heritability and shared environment estimates for myopia and associated ocular
biometric traits: the Genes in Myopia (GEM) family study. Hum Genet 121:
511–520.
53. Sandilands A, O’Regan GM, Liao H, Zhao Y, Terron-Kwiatkowski A, et al.
(2006) Prevalent and rare mutations in the gene encoding filaggrin cause
ichthyosis vulgaris and predispose individuals to atopic dermatitis. J Invest
Dermatol 126: 1770–1775.
54. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, et al. (2007)
Replication of genome-wide association signals in UK samples reveals risk loci
for type 2 diabetes. Science 316: 1336–1341.
55. Klein R, Davis MD, Magli YL, Segal P, Klein BE, et al. (1991) The Wisconsin
age-related maculopathy grading system. Ophthalmology 98: 1128–1134.
56. Krachmer JH, Purcell JJ, Jr., Young CW, Bucher KD (1978) Corneal
endothelial dystrophy. A study of 64 families. Arch Ophthalmol 96: 2036–2039.
57. Boutboul S, Black GC, Moore JE, Sinton J, Menasche M, et al. (2006) A subset
of patients with epithelial basement membrane corneal dystrophy have
mutations in TGFBI/BIGH3. Hum Mutat 27: 553–557.
58. Sundin OH, Broman KW, Chang HH, Vito EC, Stark WJ, et al. (2006) A
common locus for late-onset Fuchs corneal dystrophy maps to 18q21.2-q21.32.
Invest Ophthalmol Vis Sci 47: 3919–3926.
59. Hejtmancik JF, Kantorow M (2004) Molecular genetics of age-related cataract.
Exp Eye Res 79: 3–9.
60. Klein AP, Duggal P, Lee KE, O’Neill JA, Klein R, et al. (2005) Polygenic effects
and cigarette smoking account for a portion of the familial aggregation of
nuclear sclerosis. Am J Epidemiol 161: 707–713.
61. Nemesure B, Jiao X, He Q, Leske MC, Wu SY, et al. (2003) A genome-wide
scan for primary open-angle glaucoma (POAG): the Barbados Family Study of
Open-Angle Glaucoma. Hum Genet 112: 600–609.
62. Lalin SC, Chang S, Flynn H, Von Fricken M, Del Priore LV (2004) Familial
idiopathic macular hole. Am J Ophthalmol 138: 608–611.
63. Scott A, Strouthidis NG, Robson AG, Forsyth J, Maher ER, et al. (2007)
Bilateral epiretinal membranes in Gorlin syndrome associated with a novel
PTCH mutation. Am J Ophthalmol 143: 346–348.
64. Black GC, Mazerolle CJ, Wang Y, Campsall KD, Petrin D, et al. (2003)
Abnormalities of the vitreoretinal interface caused by dysregulated Hedgehog
signaling during retinal development. Hum Mol Genet 12: 3269–3276.
65. Girmens JF, Scheer S, Heron E, Sahel JA, Tournier-Lasserve E, et al. (2008)
Familial central retinal vein occlusion. Eye 22: 308–310.
66. Weger M, Renner W, Steinbrugger I, Cichocki L, Temmel W, et al. (2005) Role
of thrombophilic gene polymorphisms in branch retinal vein occlusion.
Ophthalmology 112: 1910–1915.
67. Go SL, Hoyng CB, Klaver CC (2005) Genetic risk of rhegmatogenous retinal
detachment: a familial aggregation study. Arch Ophthalmol 123: 1237–1241.
Density Complex Ocular Traits
PLoS ONE | www.plosone.org 7 June 2008 | Volume 3 | Issue 6 | e2510